In the version of this article initially published, on p. 1235, line 32, the wrong MTases were given for the motif GATC. Instead of "…GATC (for M.EcoGI and M.EcoGII)…, " it should have read, "…GATC (for M.EcoGV and M.EcoGVII)…. " The error has been corrected for the PDF and HTML versions of this article.
Corrigendum: Industry pursues co-stimulatory receptor immunomodulators to treat cancer In the version of this article initially published, in Table 1 , the percentage of money placed into profitable biotechs in 2012 was incorrectly listed as 0.49. The correct percentage is 0.44. Also, in Table 3 , the investor group Edmond de Rothschild Investment Partners was incorrectly listed as Rothschild. In Table 5 , the "Other" category for investment in therapeutic modalities in 2011 was incorrectly listed as 812; the correct amount is 841. In Table 7 , the total number of life sciences spinouts over the 2008-2012 period was incorrectly listed as 47,000. The correct number is 471. 
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